Blood pressure should be measured at every routine clinical care visit (15). At the initial visit, blood pressure should be measured in both arms to detect and account for abnormalities that may lead to spurious blood pressures, such as arterial stenosis. Patients with elevated blood pressure ($140/90 mmHg) who are not known to have hypertension should have elevated blood pressure confirmed on a separate day, within 1 month, to confirm the diagnosis of hypertension.
Office-based semiautomated oscillometric blood pressure (conventional or office blood pressure) is the conventional method used to diagnose hypertension and monitor treatment response. Blood pressure should be measured by a trained individual (15) in the seated position, with feet on the floor and arm supported at heart level. Cuff size should be appropriate for the upper-arm circumference (Table 1) . To reduce withinpatient variability, blood pressure should be measured after 5 min of rest, 2-3 readings should be taken 1-2 min apart, and blood pressure measurements should be averaged (16). It is particularly important to make and average repeated measurements of blood pressure for the diagnosis of hypertension and titration of antihypertensive treatment.
Automated office blood pressure (AOBP) is an alternate method to measure blood pressure in which a fully automated device is used to make and average multiple readings (usually 3-5) taken over a few minutes, ideally while a patient rests quietly alone (17). AOBP was used in two large, important clinical trials, Action to Control Cardiovascular Risk in Diabetes (ACCORD) (18) and Systolic Blood Pressure Intervention Trial (SPRINT) (19) . If the patient is alone when the readings are taken, the approach is also useful for diagnosing white-coat hypertension (20) . AOBP generates values 5-10 mmHg lower than conventional office readings, on average. Thus, results of trials using this technique cannot be directly applied to practices that measure conventional office blood pressure (17,21-23). With the exception of ACCORD (18), most of the evidence of benefits of hypertension treatment in people with diabetes is based on conventional office measurements.
Hypertension is defined as a sustained blood pressure $140/90 mmHg. This definition is based on unambiguous data that levels above this threshold are strongly associated with ASCVD, death, disability, and microvascular complications (1,2,24-27) and that antihypertensive treatment in populations with baseline blood pressure above this range reduces the risk of ASCVD events (4-6,28,29). The "sustained" aspect of the hypertension definition is important, as blood pressure has considerable normal variation. The criteria for diagnosing hypertension should be differentiated from blood pressure treatment targets.
Hypertension diagnosis and management can be complicated by two common conditions: masked hypertension and white-coat hypertension. Masked hypertension is defined as a normal blood pressure in the clinic or office (,140/90 mmHg) but an elevated home blood pressure of $135/85 mmHg (30); the lower home blood pressure threshold is based on outcome studies (31) demonstrating that lower home blood pressures correspond to higher office-based measurements. White-coat hypertension is elevated office blood pressure ($140/90 mmHg) and normal (untreated) home blood pressure (,135/85 mmHg) (32). Identifying these conditions with home blood pressure monitoring can help prevent overtreatment of people with white-coat hypertension who are not at elevated risk of ASCVD and, in the case of masked hypertension, allow proper use of medications to reduce side effects during periods of normal pressure (33, 34) .
Home blood pressure measurements include daytime blood pressure measured with ambulatory blood pressure monitoring as well as measurements taken with home blood pressure monitors. The cuff size is very important, as too small a cuff will give higher than actual blood pressure values and too large a cuff will give values that are lower than actual blood pressure. The correct cuff size, such that the bladder encircles 80% of the arm (Table 1) , should be used. The cuff should be placed such that the middle is on the patient's upper arm at the level of the right atrium (the midpoint of the sternum), and it should never be placed over clothes.
Orthostatic Hypotension
Diabetic autonomic neuropathy or volume depletion can cause orthostatic hypotension (35), which may be further exacerbated by antihypertensive medications. The definition of orthostatic hypotension is a decrease in systolic blood pressure of 20 mmHg or a decrease in diastolic blood pressure of 10 mmHg within 3 min of standing when compared with blood pressure from the sitting or supine position (36). Orthostatic hypotension is common in people with type 2 diabetes and hypertension and is associated with an increased risk of mortality and heart failure (37).
It is important to assess for symptoms of orthostatic hypotension to individualize blood pressure goals, select the most appropriate antihypertensive agents, and minimize adverse effects of antihypertensive therapy. Additionally, antihypertensive medication type or timing (switch to nocturnal dosing) may require adjustment. In particular, a-blockers and diuretics may need to be stopped. People with orthostatic hypotension may benefit from support stockings or other approaches (38). Table 2 . In ACCORD BP, intensive blood pressure control did not reduce total major atherosclerotic cardiovascular events but did reduce the risk of stroke, at the expense of increased adverse events (18). Specifically, compared with a target systolic blood pressure ,140 mmHg, a target systolic blood pressure ,120 mmHg resulted in no significant difference in the primary composite outcome of MI, stroke, or cardiovascular death (hazard ratio 0.88, 95% CI 0.73 to 1.06). Stroke was reduced by 41% (hazard ratio 0.59, 95% CI 0.39 to 0.89), but serious adverse events attributed to antihypertensive therapy occurred in 3.3% vs. 1.3% of participants, with significantly increased incidence of hypotension, electrolyte abnormalities, and elevated serum creatinine. Therefore, the ACCORD BP results suggest that blood pressure targets more intensive than ,140/90 mmHg may be reasonable in selected patients who have been educated about added treatment burden, side effects, and costs (18,42). The achieved blood pressure in ADVANCE in the intervention group (136/73) was 
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Meta-analyses of Trials
Meta-analyses of placebo-controlled clinical trials using multiple classes of antihypertensive medications clearly demonstrate that antihypertensive treatment in general reduces the risks of ASCVD, heart failure, retinopathy, albuminuria, and mortality among people with diabetes (4-8,40). Overall, compared with people without diabetes, the relative benefits of antihypertensive treatment are similar, and absolute benefits may be greater (5,8,40). To clarify optimal blood pressure targets in the setting of diabetes, metaanalyses have stratified clinical trials by mean baseline blood pressure or mean blood pressure attained in the intervention or intensive treatment arm. Based on these analyses, antihypertensive treatment appears to be beneficial when mean baseline blood pressure is $140/90 mmHg or mean attained intensive blood pressure is $130/80 mmHg (4,6-8). Among trials with lower baseline or achieved blood pressure, antihypertensive treatment reduced the risk of stroke, retinopathy, and albuminuria, but effects on other ASCVD and heart failure were not evident. A critical point is that these are all trial-level meta-analyses that are subject to confounding and imprecise in their stratification, as opposed to individuallevel meta-analyses, which are needed to best address the issue (8). In addition, meta-analyses have focused largely on treatment benefits, and additional data weighing potential harms are needed. Taken together, these meta-analyses consistently show that treating patients with baseline blood pressure $140 mmHg to targets ,140 mmHg is beneficial, while more intensive targets may offer additional though probably less robust benefits.
Individualization of Treatment Targets
Patients and clinicians should engage in a shared decision-making process to determine individual blood pressure targets, with the acknowledgment that the benefits and risks of intensive blood pressure targets are uncertain and may vary across patients. Following the ADA approach to the management of hyperglycemia, factors that influence treatment targets may include risks of treatment (e.g., hypotension, drug adverse effects), life expectancy, comorbidities including vascular complications, patient attitude and expected treatment efforts, and resources and support system (44). Specific factors to consider are the absolute risk of cardiovascular events (40,45), risk of progressive kidney disease as reflected by albuminuria, adverse effects, age, and overall treatment burden.
Patients who have higher risk of cardiovascular events (particularly stroke) or albuminuria and who can attain intensive blood pressure control relatively easily and without substantial adverse effects may be best suited to intensive blood pressure control. In contrast, patients with conditions more common in older adults, such as functional limitations, polypharmacy, and multimorbidity, may be best suited to less intensive blood pressure control. Notably, there is an absence of highquality data available to guide blood pressure targets in type 1 diabetes. Associations of blood pressure with macrovascular and microvascular outcomes in type 1 diabetes are generally similar to those in type 2 diabetes and the general population (1). Given an absence of randomized trials with clinical outcomes in type 1 diabetes, effects of antihypertensive therapy can only be extrapolated from trials in other populations, potentially drawing from both ACCORD BP and SPRINT. Of note, diastolic blood pressure, as opposed to systolic blood pressure, is a key variable predicting cardiovascular outcomes in people under age 50 years without diabetes and may be prioritized in younger adults (46,47). Though convincing data are lacking, younger adults with type 1 diabetes might more easily achieve intensive blood pressure levels and may derive substantial long-term benefit from tight blood pressure control. Although there are no well-controlled studies of diet and exercise in the treatment of elevated blood pressure or hypertension in individuals with diabetes, the Dietary Approaches to Stop Hypertension (DASH) study evaluated the impact of healthy dietary patterns in individuals without diabetes and has shown antihypertensive effects similar to those of pharmacologic monotherapy (50). A recent meta-analysis found that lifestyle intervention can help lower blood pressure in patients with type 2 diabetes (51). Medium-or high-intensity combined lifestyle counseling has shown benefit in patients selected for cardiovascular risk factors, including diabetes, for the intermediate outcomes of blood pressure, lipids, fasting blood glucose, and weight, especially over 12 to 24 months (52).
TREATMENT Lifestyle Management
Lifestyle therapy consists of reducing excess body weight through caloric restriction, restricting sodium intake (,2,300 mg/day), increasing consumption of fruits and vegetables (8-10 servings per day) and low-fat dairy products (2-3 servings per day), avoiding excessive alcohol consumption (no more than 2 servings per day in men and no more than 1 serving per day in women) (53), smoking cessation, reducing sedentary time (54), and increasing physical activity levels (55). These lifestyle strategies may also positively affect glycemic and lipid control and should be encouraged in those with even mildly elevated blood pressure. In addition, clinicians are encouraged to routinely review patient medication lists for agents that may raise blood pressure, including over-the-counter and herbal ones. As an example, one metaanalysis suggested that nonsteroidal anti-inflammatory drugs increase systolic blood pressure on average by 5 mmHg (56).
Sodium
Sodium reduction has not been tested in controlled clinical trials in people with diabetes. However, results from trials in primary hypertension have shown a reduction in systolic blood pressure of ;5 mmHg and diastolic blood pressure of 2-3 mmHg with moderate sodium reduction (from a daily intake of 200 mmol [4,600 mg] to 100 mmol [2,300 mg] of sodium per day) (57). A dose-response effect has been observed with sodium reduction. Even when pharmacologic agents are used, there may be a better response when there is concomitant salt restriction due to the volume component of hypertension.
Physical Activity
Moderately intense physical activity, such as 30-45 min of brisk walking most days of the week, has been shown to lower blood pressure (58) . Regular exercise may lower blood pressure, necessitating dose adjustment of antihypertension medications (59) . b-Blockers may reduce maximal exercise capacity, while diuretics may increase risk of dehydration. Physical activities should be promoted in all patients including older adults with physical limitations. The type and intensity of physical activities should be adapted to the preferences and functional status of the patient.
Weight Loss
Weight reduction should be considered in the management of blood pressure. The loss of 1 kg in body weight has been associated with a decrease in blood pressure of ;1 mmHg (60). Some weight-loss medications may induce increases in blood pressure levels, so these must be used with care.
Sleep Apnea
Treatment of obstructive sleep apnea has been shown to reduce blood pressure in randomized studies of people with diabetes (61). (69) . b-Blockers may be used for the treatment of coronary disease or heart failure but have not been shown to reduce mortality as blood pressure-lowering agents in the absence of these conditions (5,70).
Pharmacologic Antihypertensive Treatment
Multiple-Drug Therapy
Multiple-drug therapy is often required to achieve blood pressure targets, particularly in the setting of diabetic kidney disease.
However, the use of both ACE inhibitors and ARBs in combination is not recommended given the lack of added ASCVD benefit and increased rate of adverse eventsdnamely, hyperkalemia, syncope, and acute kidney injury (71) (72) (73) plus the dihydropyridine CCB amlodipine versus benazepril and the thiazide-like diuretic hydrochlorothiazide (68, 74) . Other such trials are needed to confirm these outcomes and assess other antihypertensive medication combinations.
Diabetic Kidney Disease
Patients with diabetes and albuminuria (UACR $30 mg/g creatinine and particularly $300 mg/g creatinine) are at increased risk of progressive kidney disease (24) [75] [76] [77] . Therefore, patients with urinary albumin excretion $300 mg/g creatinine should have an ACE inhibitor or an ARB included as part of their blood pressure-lowering regimen. Clinicians should also consider an ACE inhibitor or ARB in patients with hypertension at any level of albuminuria (urinary albumin excretion $30 mg/g creatinine) (66) .
In the absence of albuminuria, the superiority of ACE inhibitors or ARBs over other antihypertensive agents for prevention of cardiovascular outcomes has not been consistently shown (66, 69, 78, 79) , although smaller trials suggest reduction in composite cardiovascular events and reduced progression to advanced stages of kidney disease (80) (81) (82) . In general, ACE inhibitors and ARBs are considered to have similar benefits and risks, and if one is not tolerated, the other can often be used (65, 83) .
Hyperkalemia and Acute Kidney Injury
In people with diabetic kidney disease, hyperkalemia risk dramatically increases when the estimated glomerular filtration rate (eGFR) is below 45 mL/min/1.73 m 2 or serum potassium is .4.5 mEq/L while the patient is already receiving a diuretic (84). Moreover, the combination of reduced eGFR and elevated potassium in a given patient can raise the risk eightfold for hyperkalemia development if spironolactone and an ACE inhibitor or ARB are added (85) .
Thiazide-like diuretics are only effective in maintaining volume and reducing the risk of hyperkalemia down to an eGFR of 30 mL/min/1.73 m 2 (86, 87) . Below an eGFR of 30 mL/min/1.73 m 2 , a long-acting loop diuretic, such as torsemide, should be prescribed instead.
To prevent inadvertent declines in eGFR, patients treated with an ACE inhibitor or ARB should be aware of volume status and avoid volume depletion to reduce the risk for acute kidney injury. Also, in volume depleted states, risk for hyperkalemia increases (71, 72, 88) .
Bedtime Dosing
Evidence suggests an association between absence of nocturnal blood pressure dipping and ASCVD events. A meta-analysis of clinical trials found a small benefit of evening versus morning dosing of antihypertensive medications with regard to blood pressure control but no data on clinical effects (89) . In two subgroup analyses of a single subsequent randomized clinical trial, moving at least one antihypertensive medication to bedtime significantly reduced cardiovascular events, but results were based on small numbers of events (90,91). 
Monitoring
Interactions with Diabetes Medications
Hyperinsulinemia and exogenous insulin may theoretically lead to hypertension through vasoconstriction and sodium and fluid retention (100). However, insulin can also promote vasodilation, and basal insulin compared with standard care was not associated with a change in blood pressure in the Outcome Reduction With an Initial Glargine Intervention (ORIGIN) trial of people with type 2 diabetes or prediabetes (101).
Sodium-glucose cotransport 2 inhibitors are associated with a mild diuretic effect and a reduction in blood pressure of 3-6 mmHg systolic blood pressure and 1-2 mmHg diastolic blood pressure (102, 103) . Glucagon-like peptide 1 receptor agonists are also associated with a reduction in systolic/diastolic blood pressure of 2-3/0-1 mmHg (104) . (Table 3) . Since multiple agents are often necessary to achieve blood pressure targets, medication adherence issues may present as resistant hypertension. Potential barriers to medication adherence (such as cost, number of medications, and side effects) should routinely be assessed. If blood pressure remains uncontrolled despite confirmed adherence, clinicians should consider an evaluation for secondary causes of hypertension.
RESISTANT HYPERTENSION
Mineralocorticoid receptor antagonists (MRAs) are effective for management of resistant hypertension in patients with type 2 diabetes when added to existing treatment with a renin-angiotensin system (RAS) inhibitor, diuretic, and CCB (105), in part because they reduce sympathetic nerve activity (106) . MRAs also reduce albuminuria and have additional cardiovascular benefits (107) (108) (109) (110) (112) . A Cochrane systematic review did not find conclusive evidence for or against blood pressure treatment for mild to moderate preexisting hypertension to reduce the risk of preeclampsia, preterm birth, small-for-gestational-age infants, or fetal death (113) . For pregnant women at high risk of preeclampsia, low-dose aspirin is recommended starting at 12 weeks of gestation to reduce the risk of preeclampsia (114) .
For women requiring antihypertensive therapy, blood pressure should be maintained between 120 and 160 mmHg systolic and 80 and 105 mmHg diastolic, as lower blood pressure levels may be associated with impaired fetal growth. Pregnant women with hypertension and evidence of end-organ damage including cardiovascular and renal diseases may be considered for lower blood pressure targets (i.e., ,140/90 mmHg) to avoid the progression of these diseases during pregnancy.
During pregnancy, treatment with ACE inhibitors, ARBs, or spironolactone is contraindicated, as they may cause fetal damage. Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, labetalol, hydralazine, and long-acting nifedipine. Diuretics may be used during late-stage pregnancy if needed for volume control (115) . Postpartum patients with gestational hypertension, preeclampsia, and superimposed preeclampsia should have their blood pressures observed for 72 h in the hospital and for 7-10 days' postpartum (112) . Long-term follow-up is recommended for these women, as they have increased lifetime cardiovascular risk.
OLDER ADULTS (AGED ‡65 YEARS)
Arterial stiffness may develop during the aging process and contribute to an increase in systolic and decrease in diastolic blood pressure in older adults (116, 117) . Diabetes is itself associated with an increase in arterial stiffness (118) , leading to a greater age-related increase in systolic blood pressure compared with people without diabetes (119) (120) (121) . Older adults with diabetes and hypertension (mainly systolic) typically present with high risk for cardiovascular events and other age-related diseases (122) (123) (124) , difficulties achieving blood pressure targets due to arterial stiffness, and high risk of iatrogenic complications, including hypoglycemia, orthostatic hypotension, and volume depletion.
In older adults with diabetes and hypertension, functional status, comorbidities, and polypharmacy are important considerations when establishing therapeutic strategies and blood pressure goals (125) . Systolic blood pressure should be the main target of treatment. In fitter patients, a therapeutic strategy similar to that used in younger individuals may be used. In the subgroup with loss of autonomy and major functional limitations (e.g., those needing daily assistance for their basic activities), higher systolic blood pressure goals should be considered (e.g., 145-160 mmHg) and treatment should be reduced in the presence of low supine systolic blood pressure (,130 mmHg) or presence of orthostatic hypotension (125, 126) .
In older people with impaired vascular compliance, as indicated by a difference of .60 mmHg between systolic and diastolic pressures (i.e., pulse pressure), attempts to reach a target systolic pressure must be balanced against the risk of lowering diastolic pressure below 65-70 mmHg. Lowering diastolic pressures below this range in older adults may increase the risk for coronary heart disease, mortality, and other adverse cardiovascular outcomes (127) (128) (129) (130) .
When considering pharmacologic antihypertensive treatment in older adults with diabetes, note that b-blockers may mask signs of hypoglycemia, antihypertensive drugs can worsen orthostatic hypotension, and diuretics can exacerbate volume depletion. Cognitive dysfunction may affect medication-taking behaviors, particularly in the context of poor overall health status, multiple comorbidities, acute illness, polypharmacy, and poor nutrition. Tolerance of the antihypertensive treatment should be regularly assessed, especially orthostatic hypotension. 
ANTIHYPERTENSIVE TREATMENT IN THE ABSENCE OF HYPERTENSION
For people with diabetes and untreated blood pressure ,140/90 mmHg, there is little evidence that antihypertensive treatment improves health outcomes. Some have suggested treatment with an ACE inhibitor or ARB to prevent or delay diabetic kidney disease, but the data do not support such an approach. In a trial of people with type 2 diabetes and normal urine albumin excretion with and without hypertension, an ARB reduced or suppressed the development of albuminuria but increased the rate of cardiovascular events (131) . In two trials of patients without albuminuria or hypertension, one including people with type 1 diabetes (132) and the other type 2 diabetes (133), RAS inhibitors did not prevent the development of diabetic glomerulopathy assessed by kidney biopsy. Therefore, RAS inhibitors are not recommended for patients without hypertension to prevent the development of diabetic kidney disease.
CONCLUSIONS
Hypertension is a strong, modifiable risk factor for the macrovascular and microvascular complications of diabetes. Robust literature demonstrates the clinical efficacy of lowering blood pressure, with cardiovascular and microvascular benefits demonstrated for multiple classes of antihypertensive medications. Strong evidence from clinical trials and meta-analyses supports targeting blood pressure reduction to at least ,140/90 mmHg in most adults with diabetes. Lower blood pressure targets may be beneficial for selected patients with high cardiovascular disease risk if they can be achieved without undue burden, and such lower targets may be considered on an individual basis. In addition to lifestyle modifications, multiple medication classes are often needed to attain blood pressure goals. ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide-like diuretics have been demonstrated to improve clinical outcomes and are preferred for blood pressure control. For patients with albuminuria, an ACE inhibitor or ARB should be part of the antihypertensive regimen. Treatment should be individualized to the specific patient based on their comorbidities; their anticipated benefit for reduction in ASCVD, heart failure, progressive diabetic kidney disease, and retinopathy events; and their risk of adverse events. This conversation should be part of a shared decisionmaking process between the clinician and the individual patient.
FUTURE UPDATES
As more evidence becomes available to guide the assessment and treatment of hypertension among people with diabetes, updated, refined, and additional recommendations will be published in the annual ADA 
